| Properties | Information |
|---|---|
| PhytoCAT-ID | PhytoCAT-1686 |
| Phytochemical name or plant extracts | Santonin |
| PMID | 31101800 |
| Literature evidence | CONCLUSIONS The findings of this study suggest the potential for the naturally occurring sesquiterpene lactone santonin in breast cancer treatment and also suggest that it could be developed as a promising anticancer agent. |
| IUPAC name | (3S,3aS,5aS,9bS)-3,5a,9-trimethyl-3a,4,5,9b-tetrahydro-3H-benzo[g][1]benzofuran-2,8-dione |
| Phytochemicals’ class or type of plant extracts | Sesquiterpene lactone |
| Source of phytochemicals or plant Extracts | NA |
| Geographical availability | NA |
| Plant parts | NA |
| Other cancers | Breast cancer |
| Target gene or protein | NA |
| Gene or Protein evidence | NA |
| Target pathways | Finally, santonin could also block the Raf/MEK/ERK pathway in breast cancer cells. we also observed that santonin caused the arrest of the SK-BR-3 cancer cells at the G2/M phase of the cell cycle which was also concomitant with the suppression of cyclin A and B1 expression. |
| IC50 | 16 µM against SKBR-3 |
| Potency | The findings of this study suggest the potential for the naturally occurring sesquiterpene lactone santonin in breast cancer treatment and also suggest that it could be developed as a promising anticancer agent. |
| Cell line/ mice model | SKBR-3 |
| Additional information | NA |
| PubChem ID | 221071 |
| Additional PMIDs | NA |
| Additional sources of information | NA |
| Safety | NA |